Factors Influencing the Safety and Efficiency of Antifungal Prophylaxis with Posaconazole in Children with Hematological Diseases: From Genetics to Polypharmacotherapy
Open Access
- 14 May 2019
- journal article
- research article
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 35 (4) , 699-706
Abstract
The aim of this study was to determine the impact of ABCB1 polymorphism, BMI, age and drug co-administration on safety and efficiency of posaconazole (PCZ) oral suspension treatment in children with hematological diseases. Seventy children were included in the study. ABCB1 polymorphism in fifty-eight children was determined using a PCR–RFLP method. A protocol with data on the health condition, treatment and adverse events (AE), as well as a survey on treatment tolerance for the legal guardians was evaluated. Liver function tests were observed for the first 20 days, and AE during the complete medication period. For statistical analysis a χ2 test with Yates’s correction, a Pearson’s or Spearman’s correlation test was performed (p < 0.05). Genetic testing showed 24% CC, 46% CT and 30% of TT variants. PCZ prophylaxis failed in twenty cases, where change in prophylactic treatment was needed. Fifty-two children suffered from at least one mild to moderate adverse event. Sixty-five legal guardians completed the survey, most of them reported the treatment to be well tolerated. ABCB1 polymorphism had no impact on AE occurrence and posaconazole prophylaxis efficiency. Age influenced the number of gastrointestinal (p = 0.02), visual (p = 0.05), neurological (p = 0.01), dermatological (p = 0.002) and flu-like (p = 0.02) complications. AST (p = 0.03) and LDH (p = 0.008) activity presented age dependency. The concomitant use of proton pump inhibitors (PPI) had impact on liver health parameters elevation (p = 0.009) and circulatory system complications (p = 0.008). High incidence of mild to moderate AE, and other factors influencing PCZ pharmacokinetics (PPI co-administration, obesity), suggest a need for careful pediatric onco-hematology patient evaluation.Keywords
This publication has 19 references indexed in Scilit:
- Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk managementTherapeutics and Clinical Risk Management, 2013
- Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxisInternational Journal of Antimicrobial Agents, 2012
- Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantationBMC Infectious Diseases, 2012
- CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteersEuropean Journal of Clinical Pharmacology, 2012
- A Twice Daily Posaconazole Dosing Algorithm for Children With Chronic Granulomatous DiseaseThe Pediatric Infectious Disease Journal, 2011
- A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxisInternational Journal of Antimicrobial Agents, 2011
- Posaconazole salvage treatment in paediatric patients: a multicentre surveyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2010
- Factors Influencing Pharmacokinetics of Prophylactic Posaconazole in Patients Undergoing Allogeneic Stem Cell TransplantationAntimicrobial Agents and Chemotherapy, 2010
- Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host DiseaseNew England Journal of Medicine, 2007
- Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemiaEuropean Journal of Haematology, 2004